NMRI Blocks CCR5, Prevents HIV Infection

20 April 1997

In laboratory studies, scientists at the Naval Medical ResearchInstitute in Maryland, USA, have prevented T cells from making the chemokine receptor CCR5, and shut down the ability of HIV to infect the T cells.

The group blocked the expression of CD3 and CD28, which in turn blocked CCR5 production. Recent studies have shown that before the AIDS virus can infect a cell, it must link with either the CCR5 or CXCR4 receptor, as well as the CD4 receptor. If someone is born without the CCR5 gene, it is very hard to become infected with HIV, said Carl June of the research group, who added that the work demonstrates that this immunity can be artificially induced by turning off the CCR5 gene.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight